2/5 For anyone doubting AVCTs ability to win significant orders from the UK Gov, just consider for a moment, how much more efficient UK Gov testing sites could become, when a test result can be achieved in c. 10 mins, without the need to employ an expensive piece of kit.
3/5 How much quicker the stations could process their backlogs and how fewer miles people would have to drive, to get a test full stop.
How likely is it that the UK Gov would turn that opportunity down and let it be sold overseas? Possible but minimal in my view.
4/5 Most importantly of all, at this late stage in the product's development.
After the LSTM have been "evaluating the performance of prototype lateral flow tests" for nearly 2 months, how good must the data be, for AVCT to be talking up localised workplace testing...
5/5 ...and testing station roll out, in direct competition to for instance, mobile PCR testing etc etc.
Certainly goo enough to make it a valid mass screening tools, which is where we are clearly heading with this now.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1/16
I've been doing some detailed research on #STX and found something important.
With scrips growth now back on track and net pricing expanding the 2 biggest risks I could find were working capital to breakeven and a covenant breach on the SWK financing.
2/ The $5.7m AOP Milestone Monetisation + the $10m Sallyport invoice factoring facility are stated by the broker as delivering them to +cash flows by H2 2025.
The same message is coming from the company although I could imagine a small amount of additional equity in 2025.
3/ The numbers say this would be small (c. $5m) and could well be in the form of a further expansion to the Sallport facility as expanding revenues allow it.
That then leaves the SWK finance covenants.
They are based on quarterly rolling group revenues up until Q2 2025.
1/16
It's difficult to call this market but my view is that assuming no more operational glitches #TGR now steadily re-rates as the operations sign off the various stages to 30ktpa.
2/ Front-end valuations should depend on where graphite prices go but as Syrah demonstrated yesterday (graphite fines not large flake) orders are buoyant.
Forward orders there running at 90,000 tons which are 50% of their current yearly output. So substantial.
3/ Note also Syrah cannot produce for less than FOB C1 $543/t even at 15,000 tons per month output and that's fines.
It is clear after last night's presentation that TGR C1 costs have also risen but this is to be expected in this current market.
1/12
Here are Verde Agritech's expected sales targets for 2022 which were revised in May and offer a significant read across to #HMI and what it can achieve this year and also.
1/9 In a previous #HMI thread, I highlighted that the $600k write-down in the FY2021 accounts meant that trade debtors (so effectively trade receivables) almost doubled between YE 2020 and YE 2021.
1/18
I've been running an extensive exercise on Verde Agritech also a relatively new but expanding fertiliser producer based just c. 70km from #HMI in Minas Gervais in Brazil. The results to date are rather fascinating and certainly worthy of review.
2/ Verde is a TSX-listed producer with a current plant capacity nearly double the size of HMI (0.6Mtpy) but with a phase 2 expansion due to come online in 2023 which would take output to 2.4Mtpy.
So a much bigger operation to come and soon.
3/ Those that remember my 5th July numbers on #HMI sales prices will perhaps remember that they demonstrated a $53.20/t average sale price for 2021.
At the average achieved AUD/BRL for 2021 of 4.054, this equated to an average price of BRL216.